{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:22Z","timestamp":1782951082948,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pharma.2025.11.008","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:14:44Z","timestamp":1764634484000},"page":"339-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heparin against inflammation: Targeting evolution and clinical impacts"],"prefix":"10.1016","volume":"84","author":[{"given":"Daohong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2025.11.008_bib0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph9030038","article-title":"Heparin: past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.pharma.2025.11.008_bib0285","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and new applications of non-anticoagulant heparin","volume":"212","author":"Cassinelli","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0290","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2025.11.008_bib0295","first-page":"103300","article-title":"Heparin beyond anti-coagulation","volume":"69","author":"Chen","year":"2021","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.pharma.2025.11.008_bib0300","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/molecules22050749","article-title":"New applications of heparin and other glycosaminoglycans","volume":"22","author":"Lima","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.pharma.2025.11.008_bib0305","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/ph16091254","article-title":"Non-anticoagulant activities of low molecular weight heparins\u00a0\u2013\u00a0a review","volume":"16","author":"Feng","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0310","doi-asserted-by":"crossref","first-page":"792739","DOI":"10.3389\/fimmu.2021.792739","article-title":"Low-molecular-weight heparin enhanced therapeutic effects of human adipose-derived stem cell administration in a mouse model of lupus nephritis","volume":"12","author":"Matsuda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0315","doi-asserted-by":"crossref","first-page":"751014","DOI":"10.1155\/2015\/751014","article-title":"Heparin interaction with the primed polymorphonuclear leukocyte CD11b induces apoptosis and prevents cell activation","volume":"2015","author":"Cohen-Mazor","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.pharma.2025.11.008_bib0320","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/01902148.2015.1091053","article-title":"Heparin and LPS-induced COX-2 expression in airway cells: a link between its anti-inflammatory effects and GAG sulfation","volume":"41","author":"Yi","year":"2015","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.pharma.2025.11.008_bib0325","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.21873\/invivo.12991","article-title":"Thromboinflammation in sepsis and heparin: a review of literature and pathophysiology","volume":"36","author":"Vagionas","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.pharma.2025.11.008_bib0330","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtha.2022.12.002","article-title":"Targeting thromboinflammation in antiphospholipid syndrome","volume":"21","author":"Salet","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2025.11.008_bib0335","doi-asserted-by":"crossref","first-page":"1157775","DOI":"10.3389\/fmed.2023.1157775","article-title":"Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0340","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3389\/fphar.2020.01307","article-title":"The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review","volume":"11","author":"Gozzo","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0345","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cjtee.2023.04.006","article-title":"Why anticoagulant studies on sepsis fail frequently\u00a0\u2013\u00a0start with SCARLET","volume":"26","author":"Guo","year":"2023","journal-title":"Chin J Traumatol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0350","doi-asserted-by":"crossref","first-page":"109095","DOI":"10.1016\/j.thromres.2024.109095","article-title":"Efficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy: an observational study","volume":"241","author":"Ushio","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharma.2025.11.008_bib0355","doi-asserted-by":"crossref","first-page":"1389354","DOI":"10.3389\/fphar.2024.1389354","article-title":"Relationship between low molecular weight heparin calcium therapy and prognosis in severe acute kidney injury in sepsis: Mendelian randomized analysis and retrospective study","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0360","doi-asserted-by":"crossref","first-page":"1159363","DOI":"10.3389\/fphar.2023.1159363","article-title":"Low molecular weight heparin in COVID-19: benefits and concerns","volume":"14","author":"Makarem","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0365","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cts.12880","article-title":"The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study","volume":"13","author":"Shi","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.pharma.2025.11.008_bib0370","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/ph17060773","article-title":"Evaluating thromboprophylaxis strategies for high-risk pregnancy: a current perspective","volume":"17","author":"Stan\u010diakov\u00e1","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0375","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12884-023-06218-9","article-title":"Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.pharma.2025.11.008_bib0380","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ijgo.15005","article-title":"Prophylactic low-molecular-weight heparin in women with thrombophilia undergoing in vitro fertilization","volume":"164","author":"Lambert","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.pharma.2025.11.008_bib0385","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/humrep\/dex069","article-title":"Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor","volume":"32","author":"Bolnick","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.pharma.2025.11.008_bib0390","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2025.11.008_bib0395","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-0042-1760333","article-title":"Evolution of antiphospholipid syndrome","volume":"49","author":"Arachchillage","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pharma.2025.11.008_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2020.11.001","article-title":"The role of low molecular weight heparin on recurrent pregnancy loss: a systematic review and meta-analysis","volume":"60","author":"Jiang","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0405","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.pharma.2025.11.008_bib0410","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3390\/ph16040584","article-title":"Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease","volume":"16","author":"Shute","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0415","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.2147\/COPD.S340129","article-title":"COPD and anticoagulation therapy: time for a new approach?","volume":"16","author":"Petris","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.pharma.2025.11.008_bib0420","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3892\/etm.2013.1001","article-title":"Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage","volume":"5","author":"Shi","year":"2013","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.pharma.2025.11.008_bib0425","doi-asserted-by":"crossref","first-page":"13326","DOI":"10.1038\/s41598-023-40489-8","article-title":"Efficacy and safety of inhaled heparin in asthmatic and chronic obstructive pulmonary disease patients: a systematic review and a meta-analysis","volume":"13","author":"Ashmawy","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharma.2025.11.008_bib0430","doi-asserted-by":"crossref","first-page":"e115938","DOI":"10.5812\/aapm.115938","article-title":"Effect of nebulized heparin on weaning off intubated patients with acute respiratory distress syndrome (ARDS) admitted to intensive care unit (ICU): a randomized clinical trial","volume":"11","author":"Olapour","year":"2021","journal-title":"Anesth Pain Med"},{"key":"10.1016\/j.pharma.2025.11.008_bib0435","doi-asserted-by":"crossref","first-page":"444","DOI":"10.21037\/atm.2017.08.23","article-title":"Nebulized anticoagulants in lung injury in critically ill patients\u00a0\u2013\u00a0an updated systematic review of preclinical and clinical studies","volume":"5","author":"Juschten","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pharma.2025.11.008_bib0440","doi-asserted-by":"crossref","first-page":"795","DOI":"10.5152\/tjg.2023.23175","article-title":"Acute pancreatitis review","volume":"34","author":"Huang","year":"2023","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0445","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/ijms18020354","article-title":"The interplay between inflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: clinical implications","volume":"18","author":"Dumnicka","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2025.11.008_bib0450","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/JIR.S388216","article-title":"Pathogenesis and therapy of coagulation disorders in severe acute pancreatitis","volume":"16","author":"Gui","year":"2023","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.pharma.2025.11.008_bib0455","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1002\/iid3.1267","article-title":"Analysis of factors influencing onset and survival of patients with severe acute pancreatitis: a clinical study","volume":"12","author":"Qin","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.pharma.2025.11.008_bib0460","doi-asserted-by":"crossref","first-page":"1241301","DOI":"10.3389\/fmed.2023.1241301","article-title":"Low molecular weight heparin decreases mortality and major complication rates in moderately severe and severe acute pancreatitis\u00a0\u2013\u00a0a systematic review and meta-analysis","volume":"10","author":"Patoni","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0465","first-page":"e65736","article-title":"Efficacy of low-molecular-weight heparin in the treatment of severe acute pancreatitis: a comparative study at a tertiary health center","volume":"16","author":"Ca","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.pharma.2025.11.008_bib0470","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/polym14122470","article-title":"Heparin protects severe acute pancreatitis by inhibiting HMGB-1 active secretion from macrophages","volume":"14","author":"Yang","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0475","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13256-023-03995-x","article-title":"Hypertriglyceridemic pancreatitis managed with heparin and insulin: a case report","volume":"17","author":"Anbessie","year":"2023","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.pharma.2025.11.008_bib0480","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000534652","article-title":"Longitudinal analysis of prophylactic anticoagulation in primary nephrotic syndrome: low incidence of thromboembolic complications","volume":"3","author":"McDonnell","year":"2023","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.pharma.2025.11.008_bib0485","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/cells13131157","article-title":"Role of the Innate immune response in glomerular disease pathogenesis: focus on podocytes","volume":"13","author":"Issa","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.pharma.2025.11.008_bib0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2215\/CJN.02400706","article-title":"Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system","volume":"2","author":"Benck","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0495","doi-asserted-by":"crossref","first-page":"107493","DOI":"10.1016\/j.jbc.2024.107493","article-title":"Low molecular weight heparin promotes the PPAR pathway by protecting the glycocalyx of cells to delay the progression of diabetic nephropathy","volume":"300","author":"Zhang","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharma.2025.11.008_bib0500","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10719-021-10035-7","article-title":"The association between serum interleukin-1 beta and heparin sulphate in diabetic nephropathy patients","volume":"38","author":"Jiang","year":"2021","journal-title":"Glycoconj J"},{"issue":"Suppl. 2","key":"10.1016\/j.pharma.2025.11.008_bib0505","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.2337\/dc08-s251","article-title":"Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin","volume":"31","author":"Lewis","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2025.11.008_bib0510","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.3892\/mmr.2017.7697","article-title":"Low molecular weight heparin may benefit nephrotic remission in steroid\u00a0\u2013\u00a0sensitive nephrotic syndrome via inhibiting elastase","volume":"16","author":"Zhai","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharma.2025.11.008_bib0515","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4103\/0378-6323.184199","article-title":"Anticoagulants in dermatology","volume":"82","author":"Adya","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0520","doi-asserted-by":"crossref","first-page":"549417","DOI":"10.1155\/2015\/549417","article-title":"Diverse roles of heparan sulfate and heparin in wound repair","volume":"2015","author":"Olczyk","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.pharma.2025.11.008_bib0525","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221086911","article-title":"Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies","volume":"14","author":"Rodr\u00edguez-Garzotto","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0530","first-page":"743","article-title":"Effect of heparinoid moisturizer on quality of life in patients with acute radiation skin damage following hypofractionated radiation therapy after breast-conserving surgery: a randomized controlled study","volume":"13","author":"Kawamori","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.pharma.2025.11.008_bib0535","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12262-012-0674-6","article-title":"A comparative study of paediatric thermal burns treated with topical heparin and without heparin","volume":"76","author":"Venkatachalapathy","year":"2014","journal-title":"Indian J Surg"},{"key":"10.1016\/j.pharma.2025.11.008_bib0540","first-page":"277","article-title":"Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany","volume":"20","author":"Beuth","year":"2006","journal-title":"In Vivo"},{"key":"10.1016\/j.pharma.2025.11.008_bib0545","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2147\/CCID.S328671","article-title":"Glycosaminoglycans: sweet as sugar targets for topical skin anti-aging","volume":"14","author":"Wang","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.pharma.2025.11.008_bib0550","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/jocd.12857","article-title":"Global periorbital skin rejuvenation by a topical eye cream containing low molecular weight heparan sulfate (LMW-HS) and a blend of naturally derived extracts","volume":"18","author":"Colvan","year":"2019","journal-title":"J Cosmet Dermatol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925001853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925001853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:43:54Z","timestamp":1776357834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450925001853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0003450925001853"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.11.008","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin against inflammation: Targeting evolution and clinical impacts","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}